Priothera Announces First Patients Enrolled in Pivotal MO-TRANS Global Phase IIb/III Study with Mocravimod as an Adjunctive and Maintenance Therapy for Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Priothera announced that the first patients have been enrolled in the pivotal MO-TRANS global Phase IIb/III study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant.
[Haematologica] 301 patients with a median age 60 years were enrolled. Of them, 287 and 274 patients collected ≥2 and ≥4×106 CD34+ cells/kg, respectively, with a median of 9.9×106 CD34+ cells/kg collected.
[EMBO Journal] The authors provide an in-depth review of the metabolic and epigenetic interplay regulating hematopoietic stem cell fate, and discuss the influence of metabolic stress stimuli, as well as alterations occurring during leukemic development.